Immune Design Corp (NASDAQ:IMDZ) was the target of a large increase in short interest in November. As of November 15th, there was short interest totalling 1,348,299 shares, an increase of 86.6% from the October 31st total of 722,704 shares. Based on an average trading volume of 1,177,872 shares, the short-interest ratio is currently 1.1 days. Approximately 5.2% of the company’s stock are sold short.

Several equities analysts have weighed in on the company. ValuEngine upgraded Immune Design from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. BidaskClub cut Immune Design from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 5th. Royal Bank Of Canada started coverage on Immune Design in a research note on Thursday, September 14th. They set an “outperform” rating and a $20.00 target price on the stock. Zacks Investment Research cut Immune Design from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. Finally, Wells Fargo & Company cut Immune Design from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $29.00 to $10.00 in a research note on Tuesday, October 17th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. Immune Design currently has a consensus rating of “Hold” and a consensus price target of $13.19.

In related news, Director Peter Svennilson acquired 2,681,000 shares of the company’s stock in a transaction on Friday, October 27th. The shares were acquired at an average cost of $4.10 per share, for a total transaction of $10,992,100.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director Franklin M. Berger acquired 25,000 shares of the company’s stock in a transaction on Wednesday, October 25th. The shares were bought at an average price of $4.26 per share, for a total transaction of $106,500.00. Following the completion of the purchase, the director now owns 50,000 shares in the company, valued at approximately $213,000. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 5,300,000 shares of company stock worth $21,874,900. Company insiders own 20.70% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE raised its stake in shares of Immune Design by 123.3% during the 1st quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 8,418 shares during the period. State of Wisconsin Investment Board bought a new stake in shares of Immune Design during the 2nd quarter worth $117,000. Alliancebernstein L.P. bought a new stake in shares of Immune Design during the 2nd quarter worth $118,000. Virtu KCG Holdings LLC bought a new stake in shares of Immune Design during the 2nd quarter worth $153,000. Finally, Dimensional Fund Advisors LP raised its stake in Immune Design by 9.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock valued at $184,000 after acquiring an additional 1,600 shares during the period. Institutional investors own 29.38% of the company’s stock.

Shares of Immune Design (IMDZ) opened at $4.20 on Friday. Immune Design has a 52 week low of $3.78 and a 52 week high of $13.05.

Immune Design (NASDAQ:IMDZ) last released its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.52) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.11. The company had revenue of $0.52 million for the quarter, compared to analysts’ expectations of $0.62 million. Immune Design had a negative return on equity of 68.69% and a negative net margin of 619.62%. analysts anticipate that Immune Design will post -1.89 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Short Interest in Immune Design Corp (IMDZ) Grows By 86.6%” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/02/short-interest-in-immune-design-corp-imdz-grows-by-86-6.html.

Immune Design Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Receive News & Stock Ratings for Immune Design Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp and related stocks with our FREE daily email newsletter.